Compare Pfizer Inc (PFE) vs Select Medical Holdings Corporation (SEM) Price & Performance

Pfizer (PFE) trades at $24.75, down 1.2% on the day, with a neutral technical outlook. The company maintains strong fundamentals with consistent earnings beats, including Q1 2026 EPS of $0.75 beating expectations of $0.722. Pfizer demonstrates robust profitability with a 73.51% gross margin and 11.83% net income margin, though revenue has moderated from pandemic peaks. Recent news highlights the company's focus on AI drug discovery and pipeline development.

Pfizer presents a value opportunity trading below analyst consensus target of $28.25, with 38% of analysts rating it Buy. The stock offers a solid dividend yield with recent $0.43 payments. Key risks include patent expirations and revenue normalization post-COVID, while catalysts include obesity and oncology pipeline developments in 2026.

Select Medical (SEM) trades at $16.51, unchanged on the day, amid a completed acquisition by a consortium led by Robert A. Ortenzio and Martin F. at $16.50 per share. The stock shows a bullish technical signal with support and resistance clustered around $17. Financially, the company reported 2025 revenue of $5.45B and net income of $146.22M, with a P/E of 15.43 and P/S of 0.36 indicating moderate valuation. Recent earnings have been mixed, with a beat in Q3 2025 but misses in Q4 2025 and Q1 2026.

The acquisition at $16.50 per share caps near-term upside, with legal investigations into the board's fiduciary duties posing a key risk. Analyst sentiment is mixed with 35.71% buy ratings but 57.15% hold, reflecting uncertainty post-buyout. Investors should note the stock's limited movement potential given the acquisition price, with fundamental performance and legal outcomes driving any residual value.